Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
mRNA-1215 Nipah Virus Vaccine in Healthy Adults
NCT05398796Phase 1Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Jul 2022
- Primary completion
- Sep 2024
- Modality
- Vaccines & Immunotherapeutics, Lipid-based Nanoparticles, mRNA Therapeutics
- Countries
- 1
01
Overview
Phase 1, open-label trial of mRNA-1215 in Nipah virus infection (NiV) (4 arms), sponsored by National Institute of Allergy and Infectious Diseases. Primary endpoints: Number of Participants Reporting Local Reactogenicity Signs and Symptoms at 7 days, Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms at 7 days and 6 more. Started Jul 2022; status: completed.
02
Drugs
mRNA-1215
03
Conditions
Nipah virus infection (NiV)
Beyond the preview
Go deeper on NCT05398796.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05398796.